About: Evaluation of the safety, immunogenicity and pharmacokinetics of equine anti-SARS

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Evaluation of the safety, immunogenicity and pharmacokinetics of equine anti-SARS–CoV F(ab′)(2) in macaque() Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Evaluation of the safety, immunogenicity and pharmacokinetics of equine anti-SARS–CoV F(ab′)(2) in macaque()
Creator	Jia, Zhengcai Li, Jintao Liang, Yunfei Ni, Bing Wang, Li Wu, Yuzhang Xu, Yunsheng Zhou, Liyun Zhao, Tingting
Source	Elsevier; Medline; PMC
abstract	To warrant potential clinical testing, the equine anti-SARS–CoV F(ab′)(2) requires evaluation in as many animal models as possible and a safety test in a primate model. In this study, we evaluated the pharmacokinetics, tolerance and immunity of this kind of antibody in macaques and rats. Results showed that the F(ab′)(2) fragments had a normal metabolism in injected animals. The general physiological indexes did not differ between animals injected with anti-SARS–CoV F(ab′)(2) or saline. However, a mild inflammatory response in local injection site and a moderate immune response against this antibody in the successively injected animals were observed, which however recovered 3 weeks after the last injection. The antibody titring from 1:100 to 400 against the equine anti-SARS–CoV F(ab′)(2) in the inoculated hosts could be detected at week 2 during the successive injections of the equine F(ab′)(2). The considerable safety of this antibody used in primates and the fact that the immune system of the host can be motivated by post-injection of the F(ab′)(2) indicate that this type of anti-SARS–CoV antibody can be used for prevention and treatment of SASR, especially at the early stage of this virus infection. In addition, it can also provide the precious time for the combined use of other anti-SARS–CoV agents such as antiviral drug and vaccine.
has issue date	2007-12-15(xsd:dateTime)
bibo:doi	10.1016/j.intimp.2007.09.011
bibo:pmid	17996696
has license	no-cc
sha1sum (hex)	452d86f7efa0e959a7fe78d341ec9590986ec3b0
schema:url	https://doi.org/10.1016/j.intimp.2007.09.011
resource representing a document's title	Evaluation of the safety, immunogenicity and pharmacokinetics of equine anti-SARS–CoV F(ab′)(2) in macaque()
has PubMed Central identifier	PMC7106090
has PubMed identifier	17996696
schema:publication	Int Immunopharmacol
resource representing a document's body	covid:452d86f7efa0e959a7fe78d341ec9590986ec3b0#body_text
is schema:about of	named entity 'NATURAL SCIENCE' named entity 'prevention' named entity 'equine' named entity 'mild' named entity 'recovered' named entity 'equine' named entity 'GENERAL' named entity 'TREATMENT' named entity 'YOUTH' named entity 'DETECTED' named entity 'ANIMALS' named entity 'RECOVERED' named entity 'ANTIBODY' named entity 'VIRUS INFECTION' named entity 'SARS-COV' named entity 'SALINE' named entity 'INDEXES' named entity 'ANTIVIRAL DRUG' named entity 'TYPE' named entity 'USED' named entity 'OUTSTANDING' named entity 'RATS' named entity 'IMMUNITY' named entity 'TIME' named entity 'POSSIBLE' named entity 'EVALUATION' named entity 'PREVENTION' named entity 'MILD' covid:arg/452d86f7efa0e959a7fe78d341ec9590986ec3b0 named entity 'EARLY STAGE' named entity '3 WEEKS' named entity 'OBSERVED' named entity 'INJECTIONS' named entity 'PHARMACOKINETICS' named entity 'CHINA' named entity 'SCIENTIST' named entity 'NATIONAL' named entity 'COMBINED' named entity 'FACT' named entity 'IMMUNE SYSTEM' named entity 'STUDY' named entity 'INJECTION SITE' named entity 'ADDITION' named entity 'POST' named entity 'MODERATE' named entity 'ANIMAL MODELS ' named entity 'LOCAL INJECTION' named entity 'PRIMATES' named entity 'SAFETY' named entity 'CONSIDERABLE' named entity 'SUCCESSIVE' named entity 'EQUINE' named entity '80%' named entity 'MODEL' named entity 'PRIMATE' named entity 'PHYSIOLOGICAL' named entity 'NORMAL METABOLISM' named entity 'FRAGMENTS' named entity 'PROVIDE' named entity 'CLINICAL TESTING' named entity 'TOLERANCE' named entity 'HOST' named entity 'INFLAMMATORY RESPONSE' named entity 'TEST' named entity '400' named entity 'WEEK 2' named entity 'KIND' named entity 'INJECTION' named entity 'MACAQUES' named entity 'DID' named entity 'RESULTS' named entity 'POTENTIAL' named entity 'VACCINE'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software